Table 4 Uni- and multivariate linear regression analysis of variables associated with linezolid Cmin at standard dose of 600 mg every 12 h
From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients
Variables | Univariate analysis | Multivariate analysisa | ||
|---|---|---|---|---|
Unstandardized β coefficient (95%CI) | P-value | Unstandardized β coefficient (95%CI) | P-value | |
Male | −2.81 (−6.95 to 1.34) | 0.18 | ||
Age (years) (per 1-year increment) | 0.285 (0.173 to 0.396) | < 0.0001 | ||
Height (m) (per 1-m increment) | −33.71 (−51.35 to −16.07) | 0.0003 | ||
Body weight (kg) (per 1-kg increment) | −0.294 (−0.427 to −0.160) | < 0.0001 | −0.208 (−0.335 to 0.081) | 0.0016 |
CLCRC-G ≤ 60 mL/min | 11.37 (7.397 to 15.345) | < 0.0001 | 4.777 (2.793 to 6.760) | < 0.0001 |
Total bilirubin > 1.2 mg/dL | 1.111(−2.960–5.199) | 0.59 | ||
Co-treatment | ||||
Omeprazole | −1.097 (−7.273 to 5.079) | 0.73 | ||
Amiodarone | 4.676 (−1.243 to 10.595) | 0.12 | ||
Amlodipine | 1.037 (−13.885 to 15.960) | 0.89 | ||
Rifampicin | 2.236 (−5.028 to 9.501) | 0.54 | ||
Dexamethasone | 0.426 (−14.450 to 15.350) | 0.96 | ||